ArticleTrials2023

The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis.

Thomas Reiberger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.